ATE363891T1 - Injizierbare suspensionen mit verbesserten einspritzungseigenschaften - Google Patents

Injizierbare suspensionen mit verbesserten einspritzungseigenschaften

Info

Publication number
ATE363891T1
ATE363891T1 AT01928628T AT01928628T ATE363891T1 AT E363891 T1 ATE363891 T1 AT E363891T1 AT 01928628 T AT01928628 T AT 01928628T AT 01928628 T AT01928628 T AT 01928628T AT E363891 T1 ATE363891 T1 AT E363891T1
Authority
AT
Austria
Prior art keywords
suspension
viscosity
injectable compositions
injectable suspensions
injection properties
Prior art date
Application number
AT01928628T
Other languages
English (en)
Inventor
J Ramstack
M Riley
Stephen Zale
Joyce Hotz
Olufunmi Johnson
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24310496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE363891(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE363891T1 publication Critical patent/ATE363891T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01928628T 2000-05-25 2001-04-19 Injizierbare suspensionen mit verbesserten einspritzungseigenschaften ATE363891T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/577,875 US6495164B1 (en) 2000-05-25 2000-05-25 Preparation of injectable suspensions having improved injectability

Publications (1)

Publication Number Publication Date
ATE363891T1 true ATE363891T1 (de) 2007-06-15

Family

ID=24310496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928628T ATE363891T1 (de) 2000-05-25 2001-04-19 Injizierbare suspensionen mit verbesserten einspritzungseigenschaften

Country Status (26)

Country Link
US (7) US6495164B1 (de)
EP (4) EP1283699B1 (de)
JP (1) JP4502355B2 (de)
KR (1) KR100810480B1 (de)
CN (1) CN100453067C (de)
AT (1) ATE363891T1 (de)
AU (2) AU5546301A (de)
BG (1) BG66023B1 (de)
BR (1) BRPI0111060B8 (de)
CA (1) CA2406536C (de)
CY (3) CY1107441T1 (de)
CZ (1) CZ301359B6 (de)
DE (1) DE60128798T2 (de)
DK (3) DK1754469T3 (de)
ES (3) ES2574823T3 (de)
HU (1) HU228587B1 (de)
IL (1) IL152767A (de)
IS (1) IS2471B (de)
MX (1) MXPA02011543A (de)
NO (1) NO334660B1 (de)
NZ (1) NZ522335A (de)
PL (1) PL204298B1 (de)
PT (2) PT2269577E (de)
RU (1) RU2002135641A (de)
SI (2) SI1754469T1 (de)
WO (1) WO2001091720A2 (de)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
KR100525189B1 (ko) * 2002-10-10 2005-10-31 메디칸(주) 고체를 이용한 생체 부피 대체를 위한 주사용 소재
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2510196C (en) * 2002-12-20 2014-04-01 Generipharm, Inc. Intracutaneous injection
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2005013919A2 (en) * 2003-03-04 2005-02-17 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2004103342A2 (en) * 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US8092527B2 (en) * 2003-09-03 2012-01-10 Brennan William A System and method for breast augmentation
US7169180B2 (en) * 2003-09-03 2007-01-30 Brennan William A System and method for breast augmentation
BRPI0413200A (pt) 2003-09-03 2006-10-03 Miscon Trading S A método para tratamento de endometriose
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
US7906125B2 (en) * 2003-09-18 2011-03-15 Boston Scientific Scimed, Inc. Solid or semi-solid therapeutic formulations
UA82561C2 (uk) * 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
JP4947977B2 (ja) * 2003-10-31 2012-06-06 わかもと製薬株式会社 可逆性熱ゲル化水性組成物
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US8617613B2 (en) 2004-04-15 2013-12-31 Alkermes Pharma Ireland Limited Polymer-based sustained release device
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
US8236292B2 (en) * 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
EP1679065A1 (de) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8263109B2 (en) * 2005-05-09 2012-09-11 Boston Scientific Scimed, Inc. Injectable bulking compositions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
PL1971362T3 (pl) 2005-08-19 2015-05-29 Amylin Pharmaceuticals Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN103071209A (zh) 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (de) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotisches Verabreichungssystem mit Kolbenanordnung
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
CN101842084B (zh) * 2007-07-26 2014-11-05 亚克蒂斯Ip有限公司 包含pcl的微粒及其用途
SI2170279T1 (en) * 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
US20090061005A1 (en) * 2007-08-21 2009-03-05 Actavis Group Ptc Ehf Paliperidone Polymorphs
US9987221B2 (en) * 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
JP2011502990A (ja) * 2007-11-05 2011-01-27 ボーシュ アンド ローム インコーポレイティド 薬物送達用ビヒクルとしての水非混和性物質
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
WO2010005726A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EP2306991B1 (de) * 2008-06-27 2019-12-25 Tepha, Inc. Verbesserte injektionsabgabe von mikroteilchen und zusammensetzungen dafür
SI2341905T2 (sl) 2008-09-04 2024-02-29 Amylin Pharmaceuticals, Llc Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
US20100063879A1 (en) * 2008-09-05 2010-03-11 Yellowpages.Com Llc Systems and Methods to Selectively Provide Information Based on User Interest
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
EP2515942B1 (de) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutische polymernanopartikelzusammensetzungen mit hoher glasübergangstemperatur oder copolymeren von hohem molekulargewicht
US9980765B2 (en) 2010-02-15 2018-05-29 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2629775A4 (de) 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co Injizierbare formulierung mit verzögerter freisetzung
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012225268B2 (en) 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
EA027744B1 (ru) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Лекарственные формы для лечения сахарного диабета
EP2804632B1 (de) 2012-01-19 2019-09-18 The Johns Hopkins University Nanopartikelformulierungen mit verbesserter mukosaler penetration
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
HRP20210068T1 (hr) 2012-07-26 2021-03-05 Camurus Ab Opioidne formulacije
WO2014016428A1 (en) 2012-07-26 2014-01-30 Camurus Ab Opioid formulations
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
AU2015217309A1 (en) * 2014-02-11 2016-08-25 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
WO2016022831A1 (en) 2014-08-06 2016-02-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
CA2958768C (en) * 2014-08-28 2023-08-29 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6847848B2 (ja) 2014-12-15 2021-03-24 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤、及び緑内障の治療におけるその使用方法
KR20240126072A (ko) 2015-01-27 2024-08-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
US20160303281A1 (en) 2015-04-17 2016-10-20 Rochal Industries, Llc Composition and kits for pseudoplastic microgel matrices
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
CA2987619A1 (en) 2015-05-29 2016-12-08 George W. Kay Compositions and methods for adhesion to surfaces
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US10322169B2 (en) 2015-06-10 2019-06-18 Evonik Roehm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
EP3352735B1 (de) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Olanzapinformulierungen mit verzögerter freisetzung
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN105310980A (zh) * 2015-10-09 2016-02-10 北京万全德众医药生物技术有限公司 帕利哌酮缓释混悬口服液及其制备方法
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
US20200155449A1 (en) 2015-11-16 2020-05-21 Medincell Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US11564830B2 (en) 2016-02-26 2023-01-31 The General Hospital Corporation Medical ice slurry production and delivery systems and methods
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454856B1 (de) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclische degronimere für zielproteinabbau
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
EP3515408A1 (de) 2016-09-23 2019-07-31 Delpor, Inc. Stabile zusammensetzungen für inkretin-mimetische verbindungen
LT3541366T (lt) 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US10350200B2 (en) * 2017-01-23 2019-07-16 Southwest Research Institute Aqueous suspensions of oximes for autoinjectors
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
EP3600324A4 (de) 2017-03-23 2020-12-09 Graybug Vision, Inc. Arzneimittel und zusammensetzungen zur behandlung von augenkrankheiten
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
KR20240036128A (ko) 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. 침전 방지 저분자 약물 제제
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US10568842B2 (en) * 2017-08-18 2020-02-25 Lance L. Gooberman Anti-inflammatory pharmaceutical compositions and methods of administration
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
EP3773576A4 (de) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon-bindemittel zum abbau von ikaros
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
HRP20240356T1 (hr) * 2018-10-15 2024-06-07 Chong Kun Dang Pharmaceutical Corp. Injektibilni dugodjelujući pripravci mikročestica naltreksona
EP3866773B1 (de) 2018-10-16 2024-08-28 Georgia State University Research Foundation, Inc. Kohlenmonoxid-prodrugs zur behandlung von erkrankungen
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
US20220265871A1 (en) * 2019-06-14 2022-08-25 Advanced Accelerator Applications Method of Treating Cancer by Intratumoral Deposition of Radioactive Microparticles
CA3166633A1 (en) * 2020-01-03 2021-07-08 Privo Technologies, Inc. Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
BR102020021181A2 (pt) * 2020-10-16 2022-04-26 Ipanema Industria De Produtos Veterinarios Ltda Microssuspensão contra parasitas e método para sua obtenção
BE1028769B1 (nl) * 2020-11-02 2022-05-31 Flanders Color Nv Watergedragen vloeibare spoellak
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
US20240000772A1 (en) * 2021-03-15 2024-01-04 Oakwood Laboratories, Llc Microsphere formulations comprising naltrexone and methods for making and using the same
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry
KR20240041285A (ko) 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템
JP2024529009A (ja) 2021-07-06 2024-08-01 マーク・ヘースルトン セロトニン再取り込み阻害剤離脱症候群の治療
CN114146020B (zh) * 2022-02-10 2022-04-29 中国远大集团有限责任公司 一种注射美容产品及其制备方法和应用
EP4701676A1 (de) * 2023-04-28 2026-03-04 Boston Scientific Scimed, Inc. Suspensionen von röntgenopake vernetzten hydrogelpartikeln in trägerflüssigkeiten mit biokompatiblen hydrophilen polymeren
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280825A (de) 1962-07-11
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US3700215A (en) * 1970-10-21 1972-10-24 Hardman Inc Mixing and dispensing device
JPS523342B2 (de) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
JPS523653A (en) 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
IL51791A0 (en) * 1976-04-14 1977-05-31 Exxon Research Engineering Co New injectable medicinal compositions
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS60112713A (ja) * 1983-11-21 1985-06-19 Sumitomo Chem Co Ltd 有用な徐放性注射剤
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
WO1989003678A1 (en) 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
DK0471036T4 (da) 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
US6537574B1 (en) * 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
ES2152248T3 (es) 1992-02-28 2001-02-01 Collagen Corp Composiciones de colageno de alta concentracion.
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
WO1993019739A1 (en) 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
DE69327542T2 (de) 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
MY113268A (en) * 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
EP2283821A1 (de) 1993-11-19 2011-02-16 Alkermes, Inc. Herstellung biodegradierbarer Mikroteilchen, die ein biologisch aktives Mittel enthalten
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
MX9700850A (es) * 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
ATE508733T1 (de) * 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
EP1009390A4 (de) 1997-07-02 2004-05-06 Euro Celtique Sa Verlängerte narkose in gelenken und körperzwischenräumen
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP2000039867A (ja) * 1998-05-18 2000-02-08 Fujitsu Ltd プラズマディスプレイ装置およびプラズマディスプレイパネルの駆動方法
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
JP4913298B2 (ja) 1999-08-27 2012-04-11 ブルックウッド ファーマシューティカルズ，インコーポレイティド 注射可能なブプレノルフィン微粒子組成物及びその使用
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability

Also Published As

Publication number Publication date
HU228587B1 (en) 2013-04-29
WO2001091720A3 (en) 2002-05-23
NZ522335A (en) 2003-08-29
US7799345B2 (en) 2010-09-21
PL204298B1 (pl) 2009-12-31
AU2001255463B2 (en) 2004-11-04
BG107288A (bg) 2003-06-30
US6667061B2 (en) 2003-12-23
DE60128798D1 (de) 2007-07-19
HK1152660A1 (en) 2012-03-09
US20080044485A1 (en) 2008-02-21
BR0111060A (pt) 2003-04-15
CY1107441T1 (el) 2012-12-19
IS6595A (is) 2002-10-28
WO2001091720A2 (en) 2001-12-06
EP1754469A1 (de) 2007-02-21
DK1283699T3 (da) 2007-10-01
DE60128798T2 (de) 2007-10-31
DK2269577T3 (en) 2016-06-27
US20080044478A1 (en) 2008-02-21
EP1754469B1 (de) 2016-03-23
US20140193507A1 (en) 2014-07-10
BRPI0111060B1 (pt) 2019-04-16
IL152767A (en) 2008-12-29
US20040208938A1 (en) 2004-10-21
US20100303900A1 (en) 2010-12-02
HK1056321A1 (zh) 2004-02-13
CN1430501A (zh) 2003-07-16
BG66023B1 (bg) 2010-11-30
CZ301359B6 (cs) 2010-01-27
NO20025164D0 (no) 2002-10-28
KR20030020285A (ko) 2003-03-08
EP1283699B1 (de) 2007-06-06
IS2471B (is) 2008-12-15
CY1117734T1 (el) 2017-05-17
HK1054319A1 (en) 2003-11-28
PT1283699E (pt) 2007-06-22
PL365195A1 (en) 2004-12-27
JP4502355B2 (ja) 2010-07-14
DK1754469T3 (en) 2016-06-27
EP2269577B1 (de) 2016-03-16
ES2574823T3 (es) 2016-06-22
HK1103346A1 (en) 2007-12-21
EP2269577A3 (de) 2011-11-30
EP3095442A1 (de) 2016-11-23
RU2002135641A (ru) 2004-07-20
NO334660B1 (no) 2014-05-12
CA2406536A1 (en) 2001-12-06
EP3095442B1 (de) 2020-11-18
HUP0302283A2 (hu) 2003-10-28
IL152767A0 (en) 2003-06-24
US20030113380A1 (en) 2003-06-19
NO20025164L (no) 2002-11-25
MXPA02011543A (es) 2004-08-12
CA2406536C (en) 2009-12-22
ES2572877T3 (es) 2016-06-02
ES2286118T3 (es) 2007-12-01
KR100810480B1 (ko) 2008-03-07
SI2269577T1 (sl) 2016-09-30
SI1754469T1 (sl) 2016-09-30
CY1117652T1 (el) 2017-05-17
PT2269577E (pt) 2016-06-14
JP2003534366A (ja) 2003-11-18
EP2269577A2 (de) 2011-01-05
EP1283699A2 (de) 2003-02-19
BRPI0111060B8 (pt) 2021-05-25
CZ20023848A3 (cs) 2003-05-14
AU5546301A (en) 2001-12-11
US6495164B1 (en) 2002-12-17
US7371406B2 (en) 2008-05-13
HUP0302283A3 (en) 2007-02-28
CN100453067C (zh) 2009-01-21

Similar Documents

Publication Publication Date Title
ATE363891T1 (de) Injizierbare suspensionen mit verbesserten einspritzungseigenschaften
AR047652A1 (es) Una composicion para utilizarse en el lavado o tratamiento de telas
AR017264A1 (es) Agente blanqueador
PE84899A1 (es) Formulaciones farmaceuticas que contienen voriconazol
NO20023155L (no) Fremgangsmåte for endring av relativ permeabilitet til en hydrokarbon-b¶rende formasjon
WO2002038185A3 (en) Injectable sustained release delivery system with loperamide
DE60229836D1 (de) Hochlösliches sojaprotein von hohem molekulargewicht
AR011002A1 (es) Composicion de champu para estilizar el cabello
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
BR0016828A (pt) Polìmeros superabsorventes
AR048681A1 (es) Composiciones blanqueadoras liquidas
BR0214602A (pt) Método de produção de um tablete detergente, tablete detergente, e, componente de argila adequado para uso em uma formulação detergente
AR054348A1 (es) Metodos para usar resinas en formaciones subterraneas
PT1123794E (pt) Componente de plastico de elevado grau de enchimento
DE60224449D1 (de) Gebrauchsfertige paracetamol injektionslösungen enthaltend propylenglykol als einziges cosolvens
AR067111A1 (es) Resinas epoxicas con contenido de nano cargas y dispersiones acuosas estables de las mismas
BR0013120A (pt) Detergente lìquido não-aquoso, com partìculas de enchimento de baixa densidade, solúveis em água de lavagem
AR008442A1 (es) Composiciones suavizadoras liquidas de telas y metodos para proveer cuidado del color
EP1094099A4 (de) Wasser- und ölabweisende zusammensetzung vom wässrigen dispersionstyp
BR0013266A (pt) Composição, utilização de uma composição e artigo acabado
BR9815885A (pt) Composição de condicionamento de cabelo.
DE60022985D1 (de) Verstärkte polyamide mit hohem modul
BR0009173A (pt) Utilização de um agente anti-lixiviação
RU2003111817A (ru) Гидроизоляционная мастика
AR048926A1 (es) Composiciones blanqueadoras particuladas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1283699

Country of ref document: EP